Corcept Therapeutics Incorporated Share Price
NASDAQ: CORT | Large CapCorcept Therapeutics Incorporated Stock Performance
Open $110.50 | Prev. Close $110.67 | Circuit Range N/A |
Day Range $107.36 - $110.50 | Year Range $28.79 - $122.20 | Volume 59,292 |
Average Traded $108.02 |
Corcept Therapeutics Incorporated Share Price Today
As of 9 August 2026, Corcept Therapeutics Incorporated's share price is $107.89. The stock opened at $110.50, compared to its previous close of $110.67. During today's trading session, Corcept Therapeutics Incorporated's share price traded between $107.36 and $110.50, with an average price of $108.93. Over the past 52 weeks, the stock has recorded a high of $122.20 and a low of $28.79. In terms of performance, Corcept Therapeutics Incorporated's share price has risen by 202.06% over the last six months and is up 54.73% on a year-on-year basis.
Corcept Therapeutics Incorporated Share Price Chart
Corcept Therapeutics Incorporated Stock Fundamentals & Key Indicators
Market Cap $11.21B | PE Ratio (TTM) 113.57 | Dividend Yield N/A |
EPS (TTM) $0.95 | Revenue (TTM) $761.41M | Return On Equity (TTM) 15.38% |
Profit Margin 13.09% | Debt to Equity 0.26 | Quarterly Earnings Growth YoY N/A |
Corcept Therapeutics Incorporated Annual Profit & Loss
All figures in USD
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Corcept Therapeutics Incorporated Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $114.58 | $110.66 | -3.33% |
Jul 2026 | $87.27 | $114.47 | +31.76% |
Jun 2026 | $69.20 | $86.88 | +25.11% |
May 2026 | $47.64 | $69.44 | +49.33% |
Apr 2026 | $40.63 | $46.50 | +15.37% |
Mar 2026 | $34.76 | $40.30 | +12.84% |
Feb 2026 | $41.12 | $35.72 | -10.30% |
Jan 2026 | $35.65 | $39.82 | +14.46% |
Dec 2025 | $78.00 | $34.79 | -56.18% |
Nov 2025 | $73.16 | $79.39 | +8.07% |
Oct 2025 | $82.78 | $73.46 | -11.67% |
Sep 2025 | $70.00 | $83.17 | +19.27% |
CORT Share Price FAQs
What is Corcept Therapeutics Incorporated share price today?
What is the 52 week high and 52 week low of Corcept Therapeutics Incorporated stock?
What is CORT's market capitalisation today?
What is the 5 year returns of CORT?
What is the high & low stock price of CORT today?
Can I buy CORT shares in India?